{
    "organizations": [],
    "uuid": "835209e0d99c0ac88c1ba02e5bae5cbdde3b0f50",
    "author": "",
    "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-provides-2/brief-adverum-biotechnologies-provides-2018-outlook-idUSASB0BZRR",
    "ord_in_thread": 0,
    "title": "BRIEF-Adverum Biotechnologies Provides 2018 Outlook",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 49 PM / Updated 24 minutes ago BRIEF-Adverum Biotechnologies Provides 2018 Outlook Reuters Staff \nJan 4 (Reuters) - Adverum Biotechnologies Inc: * ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK \n* ADVERUM BIOTECHNOLOGIES INC - ADVERUMâ€˜S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017. \n* ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019 \n* ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T16:49:00.000+02:00",
    "crawled": "2018-01-04T17:03:08.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "biotechnology",
        "provides",
        "outlook",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "adverum",
        "biotechnology",
        "inc",
        "adverum",
        "biotechnology",
        "provides",
        "outlook",
        "adverum",
        "biotechnology",
        "inc",
        "adverum",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "september",
        "adverum",
        "biotechnology",
        "inc",
        "current",
        "cash",
        "position",
        "expected",
        "fund",
        "three",
        "lead",
        "gene",
        "therapy",
        "program",
        "end",
        "adverum",
        "plan",
        "submit",
        "investigational",
        "nda",
        "fda",
        "h2",
        "wet",
        "amd",
        "hereditary",
        "angioedema",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}